TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
許駿Hsu, Chiun
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
29筆
21
Yang SH, Guo JC, Hsu C, Kuo SH, Tien YW, Cheng AL, Yeh KH. Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients. J Formos Med Assoc. 2020 Jan;119(1 Pt 1):97-105. doi: 10.1016/j.jfma.2019.01.015. Epub 2019 Mar 7. PMID: 30852003.
22
Tsou HH, Yang HC, Hsiao CF, Hsiung CA, Liu TW, Chuang MH, Wu HY, Hsu YT, Tsui CW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. J Formos Med Assoc. 2020 Jan;119(1 Pt 2):335-344. doi: 10.1016/j.jfma.2019.05.027. Epub 2019 Jun 22. PMID: 31235201.
23
Ou DL, Lin YY, Hsu CL, Lin YY, Chen CW, Yu JS, Miaw SC, Hsu PN, Cheng AL, Hsu C. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. Liver Cancer. 2019 May;8(3):155-171. doi: 10.1159/000489318. Epub 2018 Jun 22. PMID: 31192153; PMCID: PMC6547269.
24
Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Cruz CD, Kudo M. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019 Sep;71(3):543-552. doi: 10.1016/j.jhep.2019.05.014. Epub 2019 Jun 7. Erratum in: J Hepatol. 2019 Dec;71(6):1278. PMID: 31176752.
25
Liu TH, Shao YY, Lu LC, Shen YC, Hsu C, Lin ZZ, Hsu CH, Cheng AL. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):615-621. doi: 10.1080/17474124.2019.1621165. Epub 2019 May 27. PMID: 31132887.
26
Lu LC, Hsu C, Shao YY, Chao Y, Yen CJ, Shih IL, Hung YP, Chang CJ, Shen YC, Guo JC, Liu TH, Hsu CH, Cheng AL. Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Liver Cancer. 2019 Nov;8(6):480-490. doi: 10.1159/000501275. Epub 2019 Aug 6. PMID: 31799205; PMCID: PMC6883443.
27
Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, Kuromatsu R, Moriguchi M, Chao Y, Zhao H, Anderson J, Dela Cruz C, Kudo M. Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552]. J Hepatol. 2019 Dec;71(6):1278. doi: 10.1016/j.jhep.2019.09.013. Epub 2019 Oct 25. Erratum for: J Hepatol. 2019 Sep;71(3):543-552. PMID: 31668671.
28
Lin ZZ, Hsu C, Jeng YM, Hu FC, Pan HW, Wu YM, Hsu HC, Hu MC, Cheng AL. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma. Liver Int. 2019 Sep;39(9):1682-1691. doi: 10.1111/liv.14055. Epub 2019 Jul 11. Erratum in: Liver Int. 2020 Sep;40(9):2309. Hu, Mickey C-T [added]. PMID: 30698907.
29
Shao YY, Liu TH, Hsu C, Lu LC, Shen YC, Lin ZZ, Cheng AL, Hsu CH. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int. 2019 Nov;39(11):2184-2189. doi: 10.1111/liv.14210. Epub 2019 Aug 31. PMID: 31400295.
